Kailera Therapeutics Initiates Global Phase 3 Trials for Dual GLP-1/GIP Obesity Drug Following Strong Chinese Study Results
核心洞察
Kailera Therapeutics (搜索) has begun randomizing participants in its KaiNETIC global Phase 3 program for ribupatide (搜索), a dual GLP-1 (搜索)/GIP (搜索) receptor agonist targeting obesity (搜索) treatment.
Previous Chinese trials demonstrated impressive weight loss results, with ribupatide (搜索) achieving 23.6% weight reduction after 36 weeks compared to 1.8% with placebo.
The comprehensive Phase 3 program includes three trials enrolling over 4,700 participants across multiple regions, with doses up to 10 mg evaluated over 76 weeks.
Kailera Therapeutics (搜索) has announced the randomization of first participants in its ambitious KaiNETIC global Phase 3 clinical program for ribupatide (搜索) (KAI-9531), a once-weekly injectable dual GLP-1 (搜索)/GIP (搜索) receptor agonist designed to address the growing obesity (搜索) epidemic. The milestone follows compelling results from Chinese studies that demonstrated substantial weight loss benefits, positioning the drug as a potential category leader in obesity treatment.
Strong Foundation from Chinese Clinical Data
The advancement to Phase 3 builds on robust clinical evidence generated through partnership with Hengrui Pharma in China. In a previously reported 36-week clinical trial, ribupatide (搜索) achieved a remarkable 23.6% reduction in body weight from baseline, compared to just 1.8% with placebo, based on the efficacy estimand. Notably, this substantial weight loss was achieved with only 12 weeks of treatment at the 8 mg dose, with no observed plateau in weight reduction.
Earlier Phase 2 results from a 166-patient Chinese study further validated ribupatide (搜索)'s potential. After 26 weeks, both the 25 mg and 50 mg oral doses produced a mean 12.1% weight reduction from baseline, significantly outperforming placebo's 2.3% weight loss. The drug demonstrated impressive response rates, with 59.1% of patients in the 25-mg arm achieving at least 10% weight reduction and 38.6% reaching 15% weight loss at 26 weeks.
Comprehensive Global Phase 3 Program
The KaiNETIC program represents one of the most comprehensive obesity (搜索) drug development initiatives currently underway, comprising three global, double-blind, randomized, placebo-controlled Phase 3 trials designed to evaluate weekly ribupatide (搜索) doses up to 10 mg administered by subcutaneous injection over 76 weeks.
KaiNETIC-1: Broad Obesity Population
This trial targets enrollment of approximately 1,800 adults with a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with comorbidities, excluding type 2 diabetes (搜索). The primary endpoint focuses on percentage change in body weight from baseline at Week 76.
KaiNETIC-2: Diabetes Comorbidity Focus
Designed for approximately 1,700 participants with a BMI of 27 kg/m² or greater and type 2 diabetes (搜索), this trial features co-primary endpoints of percentage change in body weight from baseline and change in hemoglobin A1c from baseline at Week 76.
KaiNETIC-3: Severe Obesity with Active Comparator
The most targeted trial will enroll approximately 1,200 adults with a BMI of 35 kg/m² or greater without type 2 diabetes (搜索). Uniquely, this study includes an open-label semaglutide 2.4 mg arm, providing direct comparison with the current standard of care. Co-primary endpoints include percentage change in body weight compared to both placebo and semaglutide 2.4 mg at Week 76.
Addressing Critical Unmet Medical Need
"Obesity (搜索) is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality," said Scott Wasserman, M.D., Chief Medical Officer at Kailera. "There remains a critical need for therapies offering greater weight loss, especially for the most severely impacted patient population – those living with a BMI greater than 35, which is projected to be half of U.S. adults with obesity by 2030."
The focus on severe obesity (搜索) addresses a significant gap in current treatment options. While existing therapies like Novo Nordisk's Wegovy and Eli Lilly's orforglipron target the GLP-1 (搜索) pathway alone, ribupatide (搜索)'s dual mechanism targeting both GLP-1 and GIP (搜索) receptors may provide enhanced efficacy for patients requiring substantial weight loss.
Favorable Safety Profile
Clinical data to date suggests ribupatide (搜索) maintains a favorable safety profile consistent with other GLP-1 (搜索)-based treatments. In the Chinese Phase 2 study, gastrointestinal side effects were manageable, with nausea affecting 22.7% of patients in the 25-mg group and vomiting occurring in 11.4%. Importantly, no patients required permanent treatment discontinuation or dose reduction due to adverse events.
Regulatory Progress and Global Expansion
Over 2,500 clinical trial participants have been dosed with ribupatide (搜索) with treatment extending up to 52 weeks across multiple late-stage clinical trials. Hengrui Pharma has submitted a marketing authorization application to China's National Medical Products Administration (NMPA) for long-term weight management, while Kailera pursues global development through the KaiNETIC program spanning North America, Europe, UK, Oceania, and South America.
"We believe ribupatide (搜索) has the potential to have a category-leading profile for the treatment of obesity (搜索)," said Ron Renaud, President and Chief Executive Officer of Kailera. "Reaching this milestone reflects the dedicated and focused effort of our team and underscores our commitment to leading the next era of obesity care."
The trials will evaluate dose titration for up to 24 weeks followed by maintenance dosing for at least 52 weeks, with both KaiNETIC-1 and KaiNETIC-2 including pre-defined subgroup analyses for participants with BMI 35 kg/m² or greater, ensuring comprehensive evaluation across the obesity (搜索) spectrum.